Form 4: Biogen Executive Jane Grogan Reports Stock Transactions
SEC Form 4
Jane Grogan, Head of Research at Biogen, reports the acquisition and disposal of common stock and restricted stock units.
Summary
- On February 7, 2025, Jane Grogan, Head of Research at Biogen, reported transactions involving Biogen's common stock and restricted stock units.
- Grogan acquired 1,385 shares of common stock through the vesting of restricted stock units.
- She also disposed of 443 shares of common stock to cover tax obligations at a price of $141.35 per share.
- Additionally, Grogan was granted 5,620 restricted stock units on February 6, 2025, which vest in three equal yearly installments beginning on February 6, 2026.
- After these transactions, Grogan directly owns 1,433 shares of common stock and 2,770 restricted stock units.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are routine and reflect standard executive compensation practices. The acquisition through vesting is mildly positive, while the disposal for tax purposes is neutral.
Positives
- The acquisition of shares through vesting indicates confidence in the company's future performance.
Negatives
- The disposal of shares to cover tax obligations, while common, slightly reduces the executive's holdings.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are closely monitored by investors for insights into management's perspective on the company's performance and future prospects.
Comparison to Industry Standards
- Executive compensation packages often include restricted stock units that vest over time, aligning executive interests with long-term shareholder value.
- The vesting schedule of the restricted stock units is typical for the industry, with vesting occurring over a three-year period.
- Tax-related disposals are a standard practice among executives receiving stock-based compensation.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding executive compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| 02/07/2024 | Grant date for restricted stock units that vest in three equal annual installments, commencing one year after this date. |
| 02/06/2025 | Grant date for 5,620 restricted stock units that vest in three equal yearly installments beginning on the first anniversary of this date. |
| 02/06/2025 | Date of transaction involving restricted stock units. |
| 02/07/2025 | Date of common stock acquisition and disposal. |
| 02/07/2025 | Date of restricted stock unit transaction. |
| 02/06/2026 | First vesting date for restricted stock units granted on February 6, 2025. |
| 02/07/2027 | Expiration date for restricted stock units. |
| 02/06/2028 | Expiration date for restricted stock units granted on February 6, 2025. |
| 02/10/2025 | Date of signature for the Form 4 filing. |
Keywords
Biogen, BIIB, Jane Grogan, Form 4, Stock Transaction, Restricted Stock Units, Head of Research, Vesting, Tax Obligations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.